Diamedica drops after FDA places stroke therapy trial on hold

DiaMedica Therapeutics

06/07/2022 22:25

** Diamedica Therapeutics shares  DMAC.O  tank 38.6% to 
$1.24 in after-market trade 
    ** FDA places on clinical hold DMAC's mid-stage trial for
its stroke treatment DM199 after three reports of low blood
pressure  urn:newsml:reuters.com:*:nBw95wJcZa
    ** Averse events resulted from switching to an IV bag
formulated from different materials in the ReMEDy2 trial
compared to the IV bag in its previous REMEDY1 trial - DMAC
    ** Says no hypotension issues reported in its ReMEDy1 trial
in which 46 patients received DM199
    ** Company plans to submit a revised ReMEDy2 trial protocol
to the FDA 
    ** Up to last close, stock down 45.8% 

 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((Nandhini.srinivasan@thomsonreuters.com))